cervical cancer
Conditions
Interventions
Experimental group:PEGylated recombinant human granulocyte stimulating factor combined active bone marrow protection
Sponsors
the Second People's Hospital of Yibin City
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years. 2. Cervical cancer was diagnosed by histopathology, and the FIGO staging was Ib2, IIa2, IIb, III, IVa patients. 3. The physical fitness ECOG score (PS) is 0-1. 4. The expected survival time is greater than 12 weeks. 5. The organ function level must meet the following requirements: Peripheral blood: absolute white blood cell count (WBC) >= 4x10^9/L, absolute neutrophil count (ANC) >= 2x10^9/L, hemoglobin >= 110g/L, platelets (PLT) >=100x10^9/L. Liver: bilirubin <= 2 times the upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 times the upper limit of normal, urea nitrogen (BUN) <= normal Upper limit x 1.5, creatinine (Cr) <= upper limit of normal x 1.5. 6. Be able to understand this trial and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who have received systemic chemotherapy or pelvic radiotherapy at present or in the past. 2. Any patient who clearly has a disease causing abnormal peripheral blood cells. 3. Those who have serious uncontrolled medical diseases or acute infections. 4. Patients with a history of mental illness. 5. Patients who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| neutropenia; | — |
Countries
China
Contacts
Public ContactWang Shanbing
The Second People's Hospital of Yibin City
Outcome results
None listed